Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 184.84M P/E - EPS this Y 43.80% Ern Qtrly Grth -
Income -110.56M Forward P/E -3.21 EPS next Y -293.30% 50D Avg Chg 19.00%
Sales 127.04M PEG -0.12 EPS past 5Y -43.36% 200D Avg Chg -33.00%
Dividend N/A Price/Book N/A EPS next 5Y 47.50% 52W High Chg -73.00%
Recommedations 1.70 Quick Ratio 1.76 Shares Outstanding 150.33M 52W Low Chg 44.00%
Insider Own 0.95% ROA -24.56% Shares Float 122.04M Beta 1.71
Inst Own 76.02% ROE - Shares Shorted/Prior 25.43M/25.43M Price 1.54
Gross Margin 7.90% Profit Margin -87.02% Avg. Volume 2,296,511 Target Price 6.75
Oper. Margin -28.39% Earnings Date May 7 Volume 1,380,581 Change -4.35%
About Heron Therapeutics, Inc.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Heron Therapeutics, Inc. News
05:47 AM Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit Outlook
04/24/24 Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
04/11/24 Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
03/28/24 Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
03/14/24 Heron Therapeutics Full Year 2023 Earnings: Beats Expectations
03/13/24 Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript
03/13/24 Q4 2023 Heron Therapeutics Inc Earnings Call
03/12/24 Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics
03/12/24 Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023
03/12/24 Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
03/07/24 Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
03/07/24 Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
03/01/24 Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
02/29/24 5 Small Drug Stocks to Buy From a Rebounding Industry
02/28/24 Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
02/23/24 12 Best Rising Penny Stocks To Buy
02/16/24 Investors in Heron Therapeutics (NASDAQ:HRTX) from five years ago are still down 90%, even after 23% gain this past week
02/12/24 Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?
02/06/24 All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy
06:44 AM Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion
HRTX Chatroom

User Image jacksonjohn750 Posted - 4 hours ago

$HRTX Where will we be after next results, may 7th?

User Image HorizonBull Posted - 11 hours ago

$HRTX may close green

User Image brunoq14 Posted - 12 hours ago

$HRTX Added at 2.48.

User Image Webfoot Posted - 13 hours ago

$HRTX so discouraging to see this go below 2.70, thought we were finally going to hold around 3 for a while. Never surprised by this stock. Maybe one day we will wake upto huge job premarket and be in our way to $20. I believe in the products Heron has and Collard leading the way to profitability but still does help ease the pain. No pun intended. 😂😂😂

User Image jacksonjohn750 Posted - 13 hours ago

$HRTX shorts are in control and until sales change that we have to trade this. I’m looking for the next jump on May 8.

User Image HorizonBull Posted - 14 hours ago

$HRTX just vain attempt to keep it below 3. bargain .

User Image astroflyery1 Posted - 14 hours ago

$OPTN $MREO $HRTX $XERS $XBI I'm very excited to announce that I have acquired 50.000 Shares of OptiNose Inc. Let's hope for the best :)

User Image HorizonBull Posted - 14 hours ago

$HRTX good opportunity to add

User Image Scientwist Posted - 17 hours ago

$HRTX Heron Therapeutics (HRTX) expected to turn a profit in 2026, with a forecasted profit of $30M. Analysts project a breakeven in 2025, with an optimistic growth rate of 69%! Sold 70 percent at 6 dollars to balance my portfolio… maybe I should have stayed… 🚀💰 #HeronTherapeutics #HRTX #biotech #investing

User Image astroflyery1 Posted - 19 hours ago

$HRTX I hope they have now enough capital to finally buyout Mereo for a high price, so we can finally move on. AstraZeneca leaps after smashing first quarter forecasts https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-beats-first-quarter-revenue-profit-estimates-2024-04-25/

User Image astroflyery1 Posted - 20 hours ago

$HRTX McKinsey faces US criminal probe over opioids work, sources say https://www.reuters.com/business/healthcare-pharmaceuticals/mckinsey-faces-us-criminal-probe-over-opioids-work-sources-say-2024-04-24/

User Image HorizonBull Posted - 1 day ago

$HRTX good chance to load again

User Image petruchio Posted - 1 day ago

$HRTX Short interest A/O 4/15 25,433,045. -100k 18.57 days to cover

User Image Webfoot Posted - 1 day ago

$HRTX just can't hold any gains until better news from Collard. Hope he is actually looking out for share holders like he said when he first took over.

User Image DawgsDrool Posted - 1 day ago

$HRTX When someone dumps 100k shares at the market on a low volume stock it tends to go down...shorts keeping a lid on this...GLTA

User Image Braddog Posted - 1 day ago

$HRTX I believe that we are not going higher because of the overhang of the additional shares that they are voting on in June. Until Collard addresses this issue. We will be stuck below $3

User Image HorizonBull Posted - 1 day ago

$HRTX

User Image Stock_Titan Posted - 1 day ago

$HRTX Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 https://www.stocktitan.net/news/HRTX/heron-therapeutics-to-report-first-quarter-2024-financial-results-on-tzramlm5l8qv.html

User Image astroflyery1 Posted - 2 days ago

$HRTX $MREO $XERS $STRO $SPY Old investment almanacs posit that if the first five trading days of the S&P500's new year are net positive or negative, it predicts a gain or loss for the full 12 months. Hocus pocus or not, the 'five-day rule' has proven correct for five years running - despite unforeseen curve balls

User Image CapeHatterastwits Posted - 2 days ago

$HRTX I’ve flipped this twice now. I have a position for a few weeks but if you know what you’re seeing you are smart to take profit. After the climb from $.55 cents it’s got to a point of these .40-.70 cents swings as of late are evident on the daily chart. These large green spikes sell off and return to base. I believe this next climb will keep this in the $3.00.

User Image NeoTrinity Posted - 2 days ago

$HRTX Here is the A/D line. Look at the accumulation since December 2023. Today, it was a show of force. There's power just waiting to be release.

User Image ShelbyRG Posted - 2 days ago

$HRTX That felt good for most of the day , now back to things as usual , hope we have more days like that soon , without the sell-off that always seems to be around when we you get hope . Been in for year's , and It's been hard , but I believe . Personally had to deal with what was given to me hospitals, still was it great pain . Stray strong Bull's , Love Ya , with Ya !

User Image KnuckleSandwich Posted - 2 days ago

$HRTX would have been nice to hold 3+...need to wait until 5/15

User Image chance111 Posted - 2 days ago

$HRTX Damn to the day traders.

User Image Braddog Posted - 2 days ago

$HRTX 6.5 M shares traded and great news and we can’t stay above $3 Hope the shorts burn in Hell!

User Image DawgsDrool Posted - 2 days ago

$HRTX Got played like a fiddle on this one...GLTA

User Image Braddog Posted - 2 days ago

$HRTX Within 11 months or Sooner, $2.9 will seem very cheap

User Image b242dogg Posted - 2 days ago

$HRTX Seems to be hard resistance once HRTX goes above $3.00. Traded above $3.00 on 14 days this year and each time, stock quickly fell back down. Not sure what it’s going to take to keep this stock above this price.

User Image Braddog Posted - 2 days ago

$HRTX The shorts and day traders not helping out the long investors

User Image greentip Posted - 2 days ago

$HRTX This happened this morning. Likely the reason for the blast off today in HRTX. "Capital One Started Heron with an Overweight and a price target of $6.00

Analyst Ratings
Capital One Overweight Apr 23, 24
Needham Buy Apr 11, 24
Needham Buy Mar 13, 24
Needham Buy Nov 15, 23
Needham Buy Aug 15, 23
Needham Buy Jul 25, 23
Needham Buy May 12, 23
Needham Buy Apr 21, 23
Evercore ISI Group Outperform Mar 24, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Forbes William P EVP, Chief Developme.. EVP, Chief Development Officer Nov 17 Buy 1.09 25,000 27,250 79,000 11/21/23
Forbes William P EVP, Chief Developme.. EVP, Chief Development Officer Nov 16 Buy 0.9399 50,000 46,995 54,000 11/20/23
MANHARD KIMBERLY EVP, Drug Developmen.. EVP, Drug Development May 03 Sell 4.76 1,504 7,159 10,872 05/04/22
Christian Waage Director Director Dec 21 Sell 9.73 300 2,919 3,200 12/23/21
Johnson Craig A Director Director Dec 21 Sell 9.73 250 2,432 2,840 12/23/21
MANHARD KIMBERLY EVP, Drug Developmen.. EVP, Drug Development Dec 23 Option 13 10,000 130,000 10,000 12/23/20
MANHARD KIMBERLY EVP, Drug Developmen.. EVP, Drug Development Dec 23 Sell 20 10,000 200,000 12/23/20